Evidence map›Paper›PMID 41403727›Full record

ArticleAdvanced pharmaceutical bulletin2025

Toll-Like Receptor-4 Signaling Pathway Influenced the Exosome Biogenesis and Angiogenesis in Human Triple-Negative Breast Cancer Cells.

Parisa Khanicheragh, Çığır Biray Avci, Zahra Abbasi-Malati, Maryam Sabour Takanlou, Leila Sabour Takanlou, Reza Rahbarghazi, Akbar Hasani

Abstract read
In one paragraph

Article in Advanced pharmaceutical bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Parisa KhanicheraghDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0001-7780-0565
Çığır Biray AvciDepartment of Medical Biology, Faculty of Medicine, Ege University, Izmir, Turkey.
Zahra Abbasi-MalatiStudent Committee Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Maryam Sabour TakanlouDepartment of Medical Biology, Faculty of Medicine, Ege University, Izmir, Turkey.
Leila Sabour TakanlouDepartment of Medical Biology, Faculty of Medicine, Ege University, Izmir, Turkey.
Reza RahbarghaziStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0003-3864-9166
Akbar HasaniDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-9461-821X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The close relationship of the toll-like receptor (TLR) signaling pathway has been indicated with different bioactivates of tumor cells. Here, the impact of TLR4 signaling pathway stimulation/inhibition was assessed on angiogenesis and exosome (Exo) biogenesis in MDA-MB-231 cells. Methods: Cells were incubated with lipopolysaccharide (LPS) and simvastatin (SIM) for 48 hours. Cell survival and TLR4 signaling pathway genes were measured using MTT and real-time PCR analysis. The physicochemical properties of Exos were studied using DLS, SEM, and western blotting. The migration capacity and angiogenesis-related genes were assessed using the Transwell insert assay and real-time PCR analysis. Results: Data indicated that SIM and LPS can reduce the survival rate in a dose-dependent manner compared to the control cells ( Conclusion: These data indicate that the TLR4 signaling pathway can control the angiogenesis and Exo production in breast cancer cells, which paves the way for the development of de novo therapies in breast cancer patients.

Indexed as

AngiogenesisBreast cancerExosomeMigrationToll-like receptor

Identifiers

PMID41403727
PMCPMC12703401

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.